MarketBeat
20 Nov 2026, 06:12 UTC · 1h ago
Arrowhead Pharmaceuticals Eyes $3 Billion REDEMPLO Opportunity as FDA Review Looms
Impact · against what's priced in
The news is largely a neutral-to-slight-positive catalyst for ARWR as it defines the timeline and scale of its commercial expansion. For IONS, the emergence of a potential competitor with a more favorable dosing and safety profile directly threatens the commercial uptake that the market is currently discounting.
- IONS−0.20
Challenges what's priced in
- The price assumes
The successful launch and commercial uptake of Tryngolza beyond initial prescriptions





